Analyst rating accuracy & track record
Matt O'Brien is an equity research analyst at Piper Sandler. Bullish Whales has scored 24 of their stock calls across 13 companies. Their picks beat their sector 24% of the time over the next 12 months, and their price targets were reached 44% of the time within a year.
Track record
Bullish Whales has scored 24 of Matt O'Brien's stock calls across 13 companies, dating back to 2021. Their rated stocks beat their own sector 24% of the time over the next 12 months. On a typical call, a O'Brien pick returned −25.5% more than its sector over the following year.
Of the scored calls, 24 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.
Coverage & ratings
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 TMDXTransMedics Group Inc | Buy | $145.00 | Jun 2025 | −63.7% | Hit |
 GMEDGlobus Medical | Buy | $80.00 | May 2025 | +22.9% | Hit |
 CVRXCVRx Inc | Buy | $12.00 | May 2025 | +38.6% | Miss |
 KIDSOrthopediatrics Corp | Buy | $30.00 | May 2025 | −29.3% | Miss |
 ATECAlphatec Holdings Inc | Buy | $15.00 | May 2025 | −20.4% | Hit |
 KMTSKestra Medical Technologies, Ltd. Common Stock | Buy | $27.00 | Mar 2025 | −23.0% | Hit |
| ATECAlphatec Holdings Inc | Buy | $13.00 | Feb 2025 | −0.8% | Hit |
 BBNXBeta Bionics, Inc. Common Stock | Buy | $26.00 | Feb 2025 | −38.0% | Hit |
 ATRCAtriCure Inc | Buy | $50.00 | Feb 2025 | −31.1% | Miss |
| CVRXCVRx Inc | Buy | $20.00 | Feb 2025 | −62.0% | Miss |
 TELATela Bio Inc | Buy | $5.00 | Nov 2024 | −59.9% | Miss |
| CVRXCVRx Inc | Buy | $16.00 | Oct 2024 | −18.9% | Hit |
| TELATela Bio Inc | Buy | $8.00 | Aug 2024 | −41.0% | Miss |
 CNMDCONMED Corporation | Buy | $80.00 | Aug 2024 | −11.3% | Miss |
| CVRXCVRx Inc | Buy | $13.00 | Jul 2024 | +5.4% | Hit |
| TELATela Bio Inc | Buy | $10.00 | May 2024 | −78.9% | Miss |
| CVRXCVRx Inc | Buy | $15.00 | May 2024 | −12.9% | Hit |
| CNMDCONMED Corporation | Buy | $95.00 | Apr 2024 | −22.2% | Miss |
| TELATela Bio Inc | Buy | $12.00 | Mar 2024 | −77.2% | Miss |
 APYXApyx Medical Inc | Buy | $4.50 | Aug 2023 | −89.6% | Hit |
 ELUTElutia Inc. | Buy | $10.50 | Nov 2022 | −77.9% | Miss |
| TELATela Bio Inc | Buy | $15.00 | Nov 2022 | −39.4% | Miss |
| APYXApyx Medical Inc | Buy | $12.00 | Aug 2022 | −38.5% | Miss |
 COOThe Cooper Companies, Inc | Buy | $435.00 | Feb 2021 | −10.5% | Hit |
Matt O'Brien: analyst track record FAQ
Is Matt O'Brien a good stock analyst?
Yes, by track record. Matt O'Brien ranks number 312 of 347 of the analysts Bullish Whales scores, with a BW Score of 0 out of 100. Past results do not guarantee future ones.
What is Matt O'Brien's win rate?
Matt O'Brien's win rate is 24%. Across 24 scored calls, their rated stocks beat their sector 24% of the time over the next 12 months. On a typical call they returned −25.5% more than the sector.
What stocks and sectors does Matt O'Brien cover?
Matt O'Brien covers 13 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.
Are Matt O'Brien's price targets accurate?
Matt O'Brien's price targets are reached within 12 months 44% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.
How accurate are Wall Street analyst price targets?
Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.
Should I follow Matt O'Brien's stock ratings?
Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.
How does Bullish Whales score analyst accuracy?
Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.
How does Matt O'Brien rank among Wall Street analysts?
Matt O'Brien ranks number 312 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.